Definitive Healthcare (NASDAQ:DH) PT Lowered to $9.50

Definitive Healthcare (NASDAQ:DH) had its price objective cut by equities research analysts at Stifel Nicolaus from $11.00 to $9.50 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 88.49% from the stock’s previous close.

A number of other equities analysts have also weighed in on the stock. Barclays lifted their price target on shares of Definitive Healthcare from $10.00 to $11.00 and gave the company an “equal weight” rating in a report on Friday, March 1st. Canaccord Genuity Group raised their price objective on Definitive Healthcare from $9.00 to $10.00 and gave the stock a “hold” rating in a report on Thursday, February 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Wednesday. Finally, Morgan Stanley downgraded shares of Definitive Healthcare from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $11.50 to $9.00 in a research note on Wednesday. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $9.94.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock traded down $0.13 on Wednesday, hitting $5.04. The company’s stock had a trading volume of 145,301 shares, compared to its average volume of 637,825. Definitive Healthcare has a 52-week low of $4.38 and a 52-week high of $12.45. The company has a market capitalization of $593.66 million, a P/E ratio of -2.90, a price-to-earnings-growth ratio of 6.12 and a beta of 1.41. The company has a quick ratio of 2.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.20. The firm has a fifty day moving average price of $7.61 and a 200-day moving average price of $8.27.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The company had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. On average, equities research analysts expect that Definitive Healthcare will post 0.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds have recently modified their holdings of the stock. Arizona State Retirement System lifted its position in Definitive Healthcare by 13.6% in the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock worth $142,000 after purchasing an additional 1,701 shares during the period. OLD National Bancorp IN grew its stake in shares of Definitive Healthcare by 14.5% during the third quarter. OLD National Bancorp IN now owns 20,613 shares of the company’s stock worth $165,000 after purchasing an additional 2,609 shares during the period. Corton Capital Inc. boosted its stake in Definitive Healthcare by 17.0% during the 3rd quarter. Corton Capital Inc. now owns 19,964 shares of the company’s stock worth $160,000 after acquiring an additional 2,898 shares during the last quarter. Swiss National Bank grew its stake in Definitive Healthcare by 2.9% in the first quarter. Swiss National Bank now owns 103,300 shares of the company’s stock valued at $834,000 after acquiring an additional 2,900 shares during the period. Finally, Wrapmanager Inc. raised its holdings in Definitive Healthcare by 10.8% during the 3rd quarter. Wrapmanager Inc. now owns 36,501 shares of the company’s stock worth $292,000 after buying an additional 3,563 shares during the period. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.